There are several types of lung cancer: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mesothelioma and lung carcinoid tumors, with NSCLC and SCLC accounting for about 95% of diagnoses (85% for NSCLC). There are also subtypes of these cancers, totaling more than a dozen types in all.
The types of lung cancer are treated very differently. Understanding treatment options, the role of different doctors specializing in the treatment of lung cancer, and how and when to access new and innovative cancer treatment options available through clinical trials is essential in order to achieve the best outcome from cancer treatment. Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged to match a person’s genetic makeup or a tumor’s genetic profile.
Lung cancer is the second most common cancer in women (behind breast cancer) and also the second most common in men (behind prostate cancer). But it is the leading cause of cancer deaths for both men and women. In 2016, there will be approximately 224,390 new cases of lung cancer, and about 158,080 will die from the disease.
As the month of November brings lung cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated lung cancer information throughout the year.
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey?
- Sign up for monthly newsletters on lung cancer here.
- Get the facts about lung cancer here.
- Join ongoing discussions with other individuals affected by lung cancer in the CancerConnect private online lung cancer community here.
- Follow CancerConnect on Facebook and Twitter.
Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes.
Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer In this study, Keytruda reduced the risk of progression or death by 50% compared to chemotherapy.
Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status In this study, 1,225 advanced or metastatic NSCLC patients whose disease had progressed following previous treatment were administered either Tecentriq or Taxotere® (docetaxel).
FDA Approves Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer.
Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases.
Copyright © 2017 CancerConnect. All Rights Reserved.